Novo Nordisk · 15 hours ago
Internship - Platform Innovation
Lexington, MA
Internship
Onsite
Intern
$52K/yr - $89K/yrNovo Nordisk is a global pharmaceutical company focused on life science innovation, seeking an intern for their Platform Innovation team. The intern will collaborate with scientists on oligonucleotide-based therapeutics, gaining hands-on experience in molecular biology and contributing to significant research projects.
BiotechnologyHealth CareMedicalPharmaceutical
No H1B
Responsibilities
Conduct molecular biology experiments: Perform gene expression analysis using techniques such as PCR/qPCR to quantify mRNA levels following siRNA treatment
Support biomarker discovery efforts: Contribute to the identification and characterization of potential biomarkers that report on therapeutic efficacy and safety
Engage in data analysis & interpretation: Analyze experimental data and draw meaningful conclusions, collaborating with platform scientists to solve real-world research problems
Participate in cross-functional teamwork: Present results and collaborate with research, development, and innovation groups focused on nucleic acid therapeutics
Qualification
Required
Must be a current student enrolled at an accredited college or university pursuing at least a bachelor's degree
Conscientious self-starter with good organizational skills, project management skills and attention to detail
Ability to balance multiple projects and priorities, must be able to multi-task
Strong interpersonal communication and ability to collaborate with teams; must effectively operate independently, across functional lines, and with internal customers
Demonstrated personal initiative, self-motivation, flexibility, adaptability and willingness to learn
Proficient in Microsoft Office Tools including Word, Excel, PowerPoint, etc
Preferred
An in progress undergraduate or graduate degree in Biology, Biochemistry, or a related discipline
Strong academic record with a preferred cumulative GPA of 3.0 or higher
Company
Novo Nordisk
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
Founded in 1923
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$22M2018-12-05Post Ipo Equity· $22M
1981-07-09IPO
Leadership Team
Lars Fruergaard Jørgensen
President and CEO
Lars Sorensen
President & CEO
Recent News
2026-02-09
Company data provided by crunchbase